Basic Neurosciences · Paper A
Reward pathway (nucleus accumbens)
Dopamine travels along four main pathways in the brain, each with its own job. For example, imagine a patient on an antipsychotic who develops both stiffness (Parkinsonism-like) and a raised prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →, those two side effects trace back to two completely different dopamine pathways being blocked, not one shared mechanism. In practice, this means each side effect must be mapped to its own pathway, since blocking one does not explain the others.
The four dopamine pathways are(1) mesolimbic (from the VTA to the nucleus accumbensA brain structure central to reward and motivation, heavily involved in addiction.Read more →), reward and addiction; too little causes anhedoniaThe loss of the ability to feel pleasure from things that used to be enjoyable.Read more → (loss of the ability to feel pleasure). (2) Mesocortical (VTA to the prefrontal cortexThe front part of the brain responsible for planning, judgement and controlling impulses.Read more →), motivation and thinking; too little gives the negative symptoms of schizophreniaA long-term mental illness involving episodes of psychosis such as hallucinations and delusions.Read more →. (3) Nigrostriatal (substantia nigraA deep brain structure rich in dopamine cells whose loss causes Parkinson's disease.Read more → to the striatum), controls movement; its loss causes Parkinson's disease. (4) Tuberoinfundibular (hypothalamusA small brain structure that controls basic functions like hunger, temperature, sleep and hormone release.Read more → to pituitary), normally holds back prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more → (the milk-producing hormone); blocking dopamine here lets prolactin rise. Picture a patient on risperidone who develops both a tremor and missed periods. Practically, an antipsychotic's side-effect profile is really a map of which of these four pathways it blocks, and by how much.
A fresh doctor might assume pleasure is just a feeling that happens after something good occurs. It is actually generated by a specific, evolutionarily old circuit, the MESOLIMBIC DOPAMINE PATHWAY (a bundle of dopamine-releasing neurons running from the midbrain to deeper forebrain structures), and understanding this circuit is the single most important building block for understanding addiction. Hold the phrase INCENTIVE SALIENCE through every section below, because it is the concept that separates "liking" something from "wanting" it, and that distinction drives most exam questions on this topic.
The reward pathway begins in the , or VTA (a cluster of dopamine-producing neurons in the midbrain), whose axons project forward to the (a small structure in the ventral striatum, part of the ) and onward to the and other limbic structures such as the . When a rewarding event occurs (food, sex, social approval, or a drug of abuse) dopamine is released from VTA terminals into the nucleus accumbens, and this release is the shared final step by which very different rewarding experiences reinforce behaviour.
A common mistake is treating the as a single "pleasure button" that lights up only for drugs. The same circuit is engaged by natural rewards, including food, social connection, and money, which is exactly why it evolved in the first place: drugs of abuse are potent partly because they hijack a circuit built for survival-relevant rewards, producing a far larger or more direct dopamine surge than most natural rewards achieve.
A rewarding or reward-predicting stimulus activates VTA dopamine neurons, which fire and release dopamine at their terminals. For example, a hungry animal that sees food after learning a food-predicting cue shows dopamine firing to the CUE itself, not just the food, once the association is learned: this is the basis of cue-triggered craving in addiction, where a lighter or a familiar street corner can trigger dopamine release before any drug is taken. This is why the pathway is often called the rather than simply "the pleasure centre."
A critical, frequently examined distinction is that dopamine in this pathway mainly encodes WANTING (incentive salience: the motivational pull toward a cue or substance) rather than pure LIKING (the hedonic pleasure of consuming it). Imagine a person with severe addiction who reports little enjoyment from using a drug anymore, yet still experiences an overwhelming urge to seek it out when they see a related cue: that mismatch between reduced liking and preserved or even heightened wanting is exactly what incentive-salience theory explains, and it is why craving can persist long after the drug itself stops feeling pleasurable.
With repeated drug exposure, the reward pathway changes: dopamine responses to the drug itself can blunt (, partly explaining escalating doses), while the incentive-salience response to drug-associated cues can become sensitised (stronger over time), sustaining relapse risk even after long abstinence. This helps explain why a person can relapse suddenly after seeing an old cue, months or years after their last use, without any new stressor.
Different substances act on this circuit through different mechanisms: stimulants such as cocaine and amphetamines directly increase synaptic dopamine (cocaine by blocking its reuptake, amphetamine by promoting its release); opioids increase VTA dopamine neuron firing indirectly by inhibiting local inhibitory neurons that normally restrain them; alcohol and nicotine also ultimately raise dopamine in the through distinct receptor mechanisms. Despite these different starting points, the convergent final pathway, increased nucleus accumbens dopamine, is the shared reinforcing step across substance use disorders.
The mesolimbic (reward) pathway is one of four classic dopamine pathways and is routinely confused with the other three, especially in exam questions about antipsychotic side effects. The ( to striatum) governs voluntary movement: blocking dopamine here causes extrapyramidal side effects, not reduced craving. The mesocortical pathway (VTA to ) is linked to cognition and negative symptoms of psychosis, and under-activity here is associated with apathy, not craving. The ( to pituitary) controls release: blocking it causes . Only the mesolimbic pathway is the one meant when a question refers to "the reward pathway" or craving specifically.
Recognising the reward pathway's role is central to understanding substance use disorder as a diagnosis. Both ICD-11 and DSM-5 define it around a cluster of behavioural and physiological features (impaired control over use, craving, , withdrawal, and continued use despite clear harm) rather than around any direct measurement of dopamine itself; formal diagnostic criteria, applied through a structured clinical history, are what a clinician actually uses to confirm the diagnosis, not the underlying pathway biology. Screening tools such as AUDIT for alcohol or brief structured interviews are used in practice to flag a possible problem before the full diagnostic threshold is formally assessed.
Management combines psychosocial approaches (motivational interviewing and relapse-prevention therapy, both informed by NICE guidance on drug and alcohol use disorders) with pharmacological options that work partly through this same pathway, such as opioid substitution therapy (methadone or buprenorphine) or naltrexone (an opioid used in relapse prevention for opioid and alcohol use disorders), following Maudsley Prescribing Guidelines. Cue-triggered craving, explained by incentive salience above, is a direct clinical target: relapse-prevention work explicitly trains patients to recognise and manage high-risk cues rather than assuming willpower alone is sufficient.
Questions often describe a patient who no longer enjoys a substance but keeps craving it, expecting the candidate to identify incentive sensitisation (wanting outlasting liking) rather than simply labelling this as "denial" or worsening pleasure. Another trap asks which structure is the key relay in the and expects the VTA-to-nucleus-accumbens projection specifically, not the or , which are downstream or parallel structures rather than the origin of the dopamine signal.
The reward pathway runs from the VTA to the , releasing dopamine mainly in response to cues that predict reward rather than to pleasure itself, which is why craving (wanting) can outlast enjoyment (liking) and why NICE- and Maudsley-informed management targets cue-triggered craving directly.